Cadena Bonfanti

Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897

Peter R Rossing, Ellen Burgess, Rajiv Agarwal, Stefan D. Anker et autres

In Fig. 2 of the article cited above, due to a typographical error, the hazard ratio (HR) of the key secondary composite kidney outcome in the insulin at baseline subgroup was incorrectly reported as 0.74 (95% CI 0.59–0.94) instead of the correct …

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Ellen Burgess, Rajiv Agarwal, Stefan D. Anker, Gerasimos S Filippatos et autres

OBJECTIVE: Finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial. We explored whether baseline HbA1c level and insulin treatment …

dk, ca, us, de, gr, es, be, au, il (code pays fourni par la source)